IRIDEX (IRIX) vs. Invivo Therapeutics (NVIV) Head-To-Head Review

IRIDEX (NASDAQ: IRIX) and Invivo Therapeutics (NASDAQ:NVIV) are both small-cap computer and technology companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, valuation, earnings and profitability.

Earnings & Valuation

This table compares IRIDEX and Invivo Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
IRIDEX $46.16 million 1.89 -$11.71 million ($1.71) -4.40
Invivo Therapeutics N/A N/A -$23.43 million ($0.85) -0.62

IRIDEX has higher revenue and earnings than Invivo Therapeutics. IRIDEX is trading at a lower price-to-earnings ratio than Invivo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

IRIDEX has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, Invivo Therapeutics has a beta of 2.71, indicating that its share price is 171% more volatile than the S&P 500.

Profitability

This table compares IRIDEX and Invivo Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
IRIDEX -42.22% -23.21% -19.03%
Invivo Therapeutics N/A -134.23% -109.16%

Institutional and Insider Ownership

49.3% of IRIDEX shares are held by institutional investors. Comparatively, 12.8% of Invivo Therapeutics shares are held by institutional investors. 5.0% of IRIDEX shares are held by insiders. Comparatively, 3.9% of Invivo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations for IRIDEX and Invivo Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IRIDEX 0 0 1 0 3.00
Invivo Therapeutics 0 1 0 0 2.00

IRIDEX presently has a consensus price target of $13.00, indicating a potential upside of 72.87%. Invivo Therapeutics has a consensus price target of $6.00, indicating a potential upside of 1,032.72%. Given Invivo Therapeutics’ higher possible upside, analysts clearly believe Invivo Therapeutics is more favorable than IRIDEX.

Summary

IRIDEX beats Invivo Therapeutics on 8 of the 13 factors compared between the two stocks.

About IRIDEX

IRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Company operates through ophthalmology segment. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes, and are used in the treatment of serious eye diseases, including the over three causes of irreversible blindness, such as diabetic retinopathy, glaucoma and age-related macular degeneration (AMD). In addition, the Company’s ophthalmology products are often used in vitrectomy procedures (used to treat proliferative diabetic retinopathy, macular holes, retinal tears and detachments), which are generally performed in the operating room and require a consumable single use intraocular laser probe (EndoProbe) to deliver light to the back of the eye together with other instrumentation.

About Invivo Therapeutics

InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.

Receive News & Ratings for IRIDEX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply